<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[Ora, Inc. 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=27048></link><description><![CDATA[Ora, Inc. 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Sat, 02 May 2026 01:46:19 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><language>ko-KR</language><item><title><![CDATA[Ora® Appoints David Hollander, M.D., M.B.A., as Chief Medical Officer]]></title><link>https://www.newswire.co.kr/newsRead.php?no=824682</link><description><![CDATA[BOSTON--(Business Wire/Korea Newswire)--Ora, Inc., the world’s leading partner for ophthalmic pharmaceutical and device development, announced today the appointment of David A. Hollander, M.D., M.B.A., as Chief Medical Officer and Senior Vice-President. Dr. Hollander most recently served as Therapeutic Area Head and Vice President of clinical development at Allergan®, responsible for ...]]></description><pubDate>Fri, 29 Apr 2016 20:00:00 +0900</pubDate></item><item><title><![CDATA[Ora®, 최고의료책임자에 데이비드 홀랜더(M.D., M.B.A.) 선임]]></title><link>https://www.newswire.co.kr/newsRead.php?no=824684</link><description><![CDATA[보스턴--(Business Wire/뉴스와이어)--안과 제약 및 장비 개발 전문 세계적인 제휴사인Ora, Inc.가 오늘 데이비드 A. 홀랜더(David A. Hollander, M.D., M.B.A.)를 최고의료책임자(Chief Medical Officer) 겸 수석부사장에 임명한다고 발표했다. 홀랜더 박사는 가장 최근에 엘러간(Allergan®)에서 치료영역 총괄 겸 임상개발 부사장으로 재직하며 전안부 안과(anterior segment ophthalmology) 및 아이케어 소비...]]></description><pubDate>Fri, 29 Apr 2016 20:00:00 +0900</pubDate></item></channel></rss>